A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)

Phase 1 Completed 16 enrolled Merck Sharp & Dohme LLC

NaSingle-groupOpen-labelBasic science

Summary

The goal of the study is to learn what happens to MK-4482 after single and multiple doses in healthy Chinese participants over time. Researchers also want to learn about the safety of MK-4482, including how well people tolerate it.

Timeline

Start: 2023-06-28
Primary completion: 2023-08-05
Completion: 2023-08-05

Publications

Results Zhu J, Zhang D, Liu Z, Yan B, Zang Y, Zhao W, Sun F, Maas BM, Cheng MH, Stoch SA, Li H. Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open-Label, Fixed Sequence, Phase 1 Study. Clin Transl Sci. 2026 Apr;19(4):e70481. doi: 10.1111/cts.70481.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Molnupiravir	Small molecule	800 mg	Oral

Indications

No indication recorded.